Reyataz 150 mg Hard Capsules
- Name:
Reyataz 150 mg Hard Capsules
- Company:
Bristol-Myers Squibb Pharma EEIG
- Active Ingredients:
- Legal Category:
Product subject to medical prescription which may not be renewed (A)
Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 21/09/20
(Click to Download)XPIL
1. What REYATAZ is and What it is used for
1. What REYATAZ is and What it is used for
2. What you need to know before you take REYATAZ
2. What you need to know before you take REYATAZ
3. How to take REYATAZ
3. How to take REYATAZ
4. Possible side effects
4. Possible side effects
5. How to store REYATAZ
5. How to store REYATAZ
6. Contents of the pack and other information
6. Contents of the pack and other information
Click on this link to Download PDF directly
Bristol-Myers Squibb Pharma EEIG
Company Products
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Updated on 21 September 2020 PIL
Reasons for updating
- XPIL Updated
Updated on 21 September 2020 PIL
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 2 - interactions with other medicines, food or drink
- Change to section 6 - date of revision
Updated on 21 September 2020 SPC
Reasons for updating
- Change to section 4.3 - Contraindications
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
SmPC 4.3 and 4.5 - to add a new contraindication and a new drug-drug interaction related to co-administration with lomiptapide
SmPC 4.5 - to add a new drug-drug interaction related to co-administration with DOACs
SmPC 4.5 - to delete drug-drug interaction related to co-administration with boceprevir
Updated on 3 June 2020 PIL
Reasons for updating
- Change to section 6 - manufacturer
- Change to section 6 - date of revision
Free text change information supplied by the pharmaceutical company
Update to Manufacturer: To add Swords Laboratories as an alternative site responsible for batch release. To change the name and amend the address of the site responsible for batch release from CATALENT Anagni
Updated on 3 June 2020 SPC
Reasons for updating
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Date of revision of the text updated to align with the Patient Leaflet date of revision of the text - 01 April 2020
Updated on 25 February 2019 PIL
Reasons for updating
- Change to section 6 - marketing authorisation holder
- Change to section 6 - date of revision
Updated on 22 February 2019 SPC
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
The Marketing Authorisation Holder address has been changed.
Updated on 26 November 2018 SPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Updated on 10 October 2018 PIL
Reasons for updating
- Change to section 2 - what you need to know - contraindications
- Change to section 2 - interactions with other medicines, food or drink
- Change to date of revision
Updated on 10 October 2018 SPC
Reasons for updating
- Change to section 4.3 - Contraindications
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
section 4.3 - amendment of text and addition of text 'Co-administration with glecaprevir/pibrentasvir fixed dose combination'
Section 4.5 - addtion of text related to co-administration of REYATAZ with glecaprevir/pibrentasvir fixed dose combination is contraindicated. Amendment of table related to interaction between reyataz and other medicinal products
Section 10 – updated date of revision
Updated on 25 May 2018 SPC
Reasons for updating
- New SPC for new product
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Include information on the contraindicated co-administration with lurasidone
- Section 4.3 Contraindactions
- Section 4.5 Interaction with other medicinal products and other forms of interaction
Updated on 18 May 2018 PIL
Reasons for updating
- Change to section 2 - what you need to know - contraindications
Updated on 13 December 2017 PIL
Reasons for updating
- New PIL for new product
Updated on 13 December 2017 PIL
Reasons for updating
- Change to section 6 - date of revision
Updated on 2 November 2017 PIL
Reasons for updating
- Change to section 2 - what you need to know - contraindications
- Change to section 6 - date of revision
Updated on 8 September 2017 PIL
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 4 January 2017 PIL
Reasons for updating
- New individual PIL (was previously included in a combined PIL)